CJC-1295 + Ipamorelin Blend: What the Research Says

Among the most studied peptide combinations in the research space, CJC-1295 and Ipamorelin are frequently examined together. Both peptides influence growth hormone (GH) secretion through different but complementary mechanisms, making their combination a popular subject of scientific inquiry.

In this guide, we break down what each peptide does individually, why researchers study them together, and what the current preclinical and clinical literature suggests about this combination.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It works by binding to GHRH receptors in the pituitary gland, stimulating the release of growth hormone. What makes CJC-1295 particularly interesting to researchers is its extended half-life compared to native GHRH.

CJC-1295 comes in two forms:

  • CJC-1295 with DAC (Drug Affinity Complex) — has a significantly longer half-life of approximately 6–8 days due to its ability to bind to albumin in the bloodstream
  • CJC-1295 without DAC (also called Modified GRF 1-29) — shorter half-life of approximately 30 minutes, producing a more pulsatile GH release pattern

What Is Ipamorelin?

Ipamorelin is a selective growth hormone secretagogue and a ghrelin mimetic. Unlike CJC-1295, which works through the GHRH pathway, Ipamorelin works through the ghrelin receptor (GHS-R1a). This distinct mechanism is key to understanding why researchers often study these two peptides in combination.

Ipamorelin is considered one of the most selective GH secretagogues studied to date. Research suggests it stimulates GH release with minimal effect on cortisol or prolactin levels, which is notable compared to other peptides in its class.

Why Are CJC-1295 and Ipamorelin Studied Together?

The combination is studied because CJC-1295 and Ipamorelin act on two separate receptor pathways that work synergistically to amplify GH release. Research suggests that when both pathways are activated simultaneously, the resulting GH pulse is significantly greater than either peptide produces alone.

Think of it this way: CJC-1295 increases the baseline signal telling the pituitary to release GH, while Ipamorelin amplifies the pulse at the receptor level. Together, they create what researchers describe as a synergistic effect on GH secretion.

What Does the Research Show?

CJC-1295 Clinical Research

CJC-1295 is one of the few peptides in this class with published human clinical trial data. A study published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 produced dose-dependent increases in GH and IGF-1 levels in healthy adults. Notably, IGF-1 levels remained elevated for up to 28 days after a single injection of the DAC formulation.

Ipamorelin Preclinical Research

Ipamorelin has been studied extensively in animal models. Research has demonstrated its ability to stimulate GH release in a dose-dependent manner while maintaining selectivity — meaning it does not significantly raise ACTH, cortisol, or prolactin at research doses. This selectivity profile has made it a particularly interesting compound for researchers studying GH modulation.

The Combination Effect

While direct human studies on the CJC-1295 + Ipamorelin combination are limited, preclinical research and mechanistic data support the rationale for studying them together. The dual-pathway activation model is well established in the endocrinology literature, and both peptides have independently demonstrated the ability to elevate GH and IGF-1 levels in research settings.

CJC-1295 + Ipamorelin Research Summary

  • CJC-1295 acts via the GHRH receptor pathway; Ipamorelin acts via the ghrelin receptor pathway
  • The combination is studied for its synergistic effect on growth hormone secretion
  • CJC-1295 has published human clinical data showing sustained IGF-1 elevation
  • Ipamorelin demonstrates high selectivity with minimal effect on cortisol or prolactin in animal studies
  • Both peptides are well-tolerated in preclinical models with no significant adverse findings at research doses
  • All research use only — neither peptide is FDA-approved for human therapeutic use

CJC-1295 vs CJC-1295 Without DAC: Which Do Researchers Use?

The choice between CJC-1295 with DAC and without DAC depends on the research protocol. The DAC version is used in studies requiring sustained GH elevation over days, while the non-DAC version is preferred in studies examining pulsatile GH release patterns that more closely mimic natural physiology. When combined with Ipamorelin, the non-DAC version is more commonly referenced in research protocols due to its shorter, more controllable activity window.

Research Use Disclaimer: CJC-1295 and Ipamorelin sold by Kinetic Peptides are intended for laboratory research purposes only. They are not intended for human consumption, veterinary use, or any use outside of controlled research settings. These peptides have not been evaluated by the FDA and are not approved to diagnose, treat, cure, or prevent any disease or condition.

Shop CJC-1295 + Ipamorelin at Kinetic Peptides

Kinetic Peptides offers both CJC-1295 (with and without DAC) and Ipamorelin individually, as well as our pre-made 2X Blend for research convenience. All products come with third-party Certificates of Analysis verifying ≥98% purity. Visit our CJC-1295 + Ipamorelin blend product page to learn more.

Related Posts